REBANIFLY Trademark

Trademark Overview

On Wednesday, February 8, 2017, a trademark application was filed for REBANIFLY with the United States Patent and Trademark Office. The USPTO has given the REBANIFLY trademark a serial number of 87328617. The federal status of this trademark filing is REGISTERED as of Tuesday, March 19, 2019. This trademark is owned by Shanghai Henlius Biotech, Inc.. The REBANIFLY trademark is filed in the Pharmaceutical Products category with the following description:

Anti-tumor drugs; anti-tumor drugs and drugs for treating autoimmune diseases
rebanifly

General Information

Serial Number87328617
Word MarkREBANIFLY
Filing DateWednesday, February 8, 2017
Status700 - REGISTERED
Status DateTuesday, March 19, 2019
Registration Number5700187
Registration DateTuesday, March 19, 2019
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 1, 2019

Trademark Statements

Goods and ServicesAnti-tumor drugs; anti-tumor drugs and drugs for treating autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 13, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameShanghai Henlius Biotech, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressShanghai 201203
CN
Party NameShanghai Henlius Biotech, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressShanghai 201203
CN
Party NameShanghai Henlius Biotech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressShanghai 201203
CN

Trademark Events

Event DateEvent Description
Tuesday, March 19, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, March 19, 2019REGISTERED-PRINCIPAL REGISTER
Saturday, January 26, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, January 26, 2019TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, January 25, 2019CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Friday, January 25, 2019WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
Thursday, January 24, 2019ASSIGNED TO PETITION STAFF
Tuesday, January 15, 2019TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, January 1, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 1, 2019PUBLISHED FOR OPPOSITION
Wednesday, December 12, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, November 19, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, November 19, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 19, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 19, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, November 13, 2018ASSIGNED TO LIE
Friday, November 2, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, November 2, 2018TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, May 4, 2018NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Friday, May 4, 2018INQUIRY TO SUSPENSION E-MAILED
Friday, May 4, 2018SUSPENSION INQUIRY WRITTEN
Saturday, November 4, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Saturday, November 4, 2017LETTER OF SUSPENSION E-MAILED
Saturday, November 4, 2017SUSPENSION LETTER WRITTEN
Thursday, November 2, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 1, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 1, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 4, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 4, 2017NON-FINAL ACTION E-MAILED
Thursday, May 4, 2017NON-FINAL ACTION WRITTEN
Wednesday, May 3, 2017ASSIGNED TO EXAMINER
Monday, February 13, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 13, 2017NEW APPLICATION ENTERED

Related Keywords

rebanifly drugs tumor anti diseases treating autoimmune